Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
To fully achieve the potential benefits of GLP-1RAs in PsA, prospective studies are needed, particularly focusing on early PsA patients to evaluate their ability to halt or even reverse musculoskeletal progression
Lancet (1987) 2(8571):13004
It encompasses trials SURPASS from 1 to 6 ( Figure 3A ), SURPASS-J (mono and combo) and SURPASS-AP, performed respectively on Japanese and Asian-Pacific population ( Figure 3B ), and SURPASS CVOT
2020 Mar 1;78(3):249-259
US$ 22.32
US$ 29.15
US$ 29.68
